TEVJF Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 10:08):

Stats
Today's Volume	150.00
Average Volume	1 883.00
Market Cap	13.17B
EPS	$0.0705 ( 2023-09-29 )
Last Dividend	$0.345 ( 2017-06-05 )
Next Dividend	$0 ( N/A )
P/E	-23.50
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-20	Fox Christine	Buy	253 968	Restricted Share Units
2023-11-20	Fox Christine	Buy	0
2023-11-15	Conway Vikki L	Buy	33 482	Restricted Share Units
2023-11-15	Bergwerk Dov	Buy	33 482	Restricted Share Units
2023-10-13	Bergwerk Dov	Sell	0	Ordinary Shares

INSIDER POWER
23.25
Last 96 transactions
Buy: 1 572 847 \| Sell: 982 807

Teva Pharmaceutical Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Teva Pharmaceutical Financials

Annual	2023
Revenue:	$15.85B
Gross Profit:	$7.65B (48.25 %)
EPS:	$-0.500

Q4	2023
Revenue:	$4.46B
Gross Profit:	$2.42B (54.21 %)
EPS:	$0.430

Q3	2023
Revenue:	$3.85B
Gross Profit:	$1.85B (48.08 %)
EPS:	$0.0699

Q2	2023
Revenue:	$3.88B
Gross Profit:	$1.80B (46.31 %)
EPS:	$-0.770

Financial Reports:

No articles found.

Teva Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Teva Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.52 - low (50.11%) | Divividend Growth Potential Score: 0.592 - No dividend growth expected in the near future

Information

First Dividend	$0.346	2014-02-24
Last Dividend	$0.345	2017-06-05
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	7	--
Total Paid Out	$2.38	--
Avg. Dividend % Per Year	0.00%	--
Score	1.84	--
Div. Sustainability Score	4.52
Div.Growth Potential Score	0.592
Div. Directional Score	2.56	--

Next Divdend (Est)
(2024-07-05)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

1.84

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
SGPYY	Ex Dividend Knight	2023-06-01	Semi-Annually	0.00%
HBSI	Ex Dividend Knight	2023-07-27	Quarterly	0.00%
ARKAY	Ex Dividend Junior	2023-05-11	Annually	0.00%
NCMGY	Ex Dividend Knight	2023-08-22	Annually	0.00%
CYFL	Ex Dividend Knight	2023-09-05	Quarterly	0.00%
SZGPY	Ex Dividend Junior	2023-05-25	Annually	0.00%
HSQVY	Ex Dividend Junior	2023-10-05	Annually	0.00%
BGAOY	Ex Dividend Knight	2023-04-26	Semi-Annually	0.00%
PCLB	Ex Dividend Knight	2023-09-01	Quarterly	0.00%
EFGXY	Ex Dividend Junior	2023-04-25	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0374	1.500	-0.748	-1.123	[0 - 0.5]
returnOnAssetsTTM	-0.0136	1.200	-0.455	-0.546	[0 - 0.3]
returnOnEquityTTM	-0.0808	1.500	-2.01	-3.01	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.019	0.800	9.90	7.92	[1 - 3]
quickRatioTTM	0.542	0.800	-1.520	-1.216	[0.8 - 2.5]
cashRatioTTM	0.263	1.500	9.65	10.00	[0.2 - 2]
debtRatioTTM	0.464	-1.500	2.27	-3.41	[0 - 0.6]
interestCoverageTTM	0.914	1.000	-0.773	-0.773	[3 - 30]
operatingCashFlowPerShareTTM	1.220	2.00	9.59	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.751	2.00	9.62	10.00	[0 - 20]
debtEquityRatioTTM	2.68	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.482	1.000	5.29	5.29	[0.2 - 0.8]
operatingProfitMarginTTM	0.0593	1.000	-0.814	-0.814	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0679	1.000	-0.734	-0.734	[0.2 - 2]
assetTurnoverTTM	0.364	0.800	-0.904	-0.723	[0.5 - 2]
Total Score				4.52

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-25.03	1.000	-2.63	0	[1 - 100]
returnOnEquityTTM	-0.0808	2.50	-1.292	-3.01	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.751	2.00	9.75	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.220	2.00	9.59	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.288	1.500	-5.26	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0863	1.000	-0.342	0	[0.1 - 0.5]
Total Score				0.592

Teva Pharmaceutical

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.